Syndax Pharmaceuticals, Inc. (SNDX) P/E Ratio History
Historical price-to-earnings valuation from 2021 to 2022
Loading P/E history...
SNDX Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
The current P/E is 108% below its 5-year average of 74.1x. Over the past five years, SNDX's P/E has ranged from a low of 50.9x to a high of 120.3x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, SNDX trades at a 128% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SNDX trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SNDX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
SNDX P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 15.5 | -Best | +1747%Best | |
| $5B | 8.3Lowest | -Best | +264% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
SNDX Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q2 | $19.24 | $0.16 | 120.3x | +62% | |
| FY2022 Q1 | $17.38 | $0.34 | 51.1x | -31% | |
| FY2021 Q4 | Fri Dec 31 2021 00:00:00 GM | $21.89 | $0.43 | 50.9x | -31% |
Average P/E for displayed period: 74.1x
See SNDX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SNDX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SNDX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSNDX — Frequently Asked Questions
Quick answers to the most common questions about buying SNDX stock.
Is SNDX stock overvalued or undervalued?
SNDX trades at -6.2x P/E, below its 5-year average of 74.1x. At the N/A percentile of historical range, the stock is priced at a discount to its own history.
How does SNDX's valuation compare to peers?
Syndax Pharmaceuticals, Inc. P/E of -6.2x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is SNDX's PEG ratio?
SNDX PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2021-2022.